<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33">
 <label>33.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Muyldermans</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Baral</surname>
    <given-names>TN</given-names>
   </name>
   <name>
    <surname>Retamozzo</surname>
    <given-names>VC</given-names>
   </name>
   <name>
    <surname>De Baetselier</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>De Genst</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Kinne</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Camelid immunoglobulins and nanobody technology.</article-title>
  <source>
   <italic>Vet Immunol Immunopathol.</italic>
  </source> (
  <year>2009</year>) 
  <volume>128</volume>:
  <fpage>178</fpage>â€“
  <lpage>83</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.vetimm.2008.10.299</pub-id>
  <?supplied-pmid 19026455?>
  <pub-id pub-id-type="pmid">19026455</pub-id>
 </mixed-citation>
</ref>
